Lyra Therapeutics, Inc. (LYRA) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LYRA Revenue Growth
LYRA Revenue Analysis (2018–2024)
As of May 9, 2026, Lyra Therapeutics, Inc. (LYRA) generated trailing twelve-month (TTM) revenue of $600,000, reflecting significant decline in growth of -87.2% year-over-year. The most recent quarter (Q3 2025) recorded $25,000 in revenue, down 86.3% sequentially.
Looking at the longer-term picture, LYRA's historical revenue data shows a 3-year CAGR of +75.3%. The company achieved its highest annual revenue of $1.6 million in 2023.
When compared to Healthcare sector peers including XNCR (-32.5% YoY), SINT (-37.7% YoY), and ARWR (+14.1% YoY), LYRA has underperformed the peer group in terms of revenue growth. Compare LYRA vs XNCR →
LYRA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LYRACurrent | $600,000 | -87.2% | - | -6280.8% | |
 XNCR | $126M | -32.5% | +0.5% | -141.4% | |
 SINT | $1M | -37.7% | +11.4% | -1053.1% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 MCRB | $789,000 | - | -52.7% | -11910.1% |
LYRA Historical Revenue Data (2018–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.5M | -1.5% | $1.5M | 100.0% | $-96,348,000 | -6280.8% |
| 2023 | $1.6M | +14.3% | $1.6M | 100.0% | $-67,120,000 | -4308.1% |
| 2022 | $1.4M | +378.2% | $1.4M | 100.0% | $-56,306,000 | -4131.0% |
| 2021 | $285K | - | $-29,409,000 | -10318.9% | $-43,615,000 | -15303.5% |
| 2020 | $0 | - | $-12,522,000 | - | $-22,209,000 | - |
| 2019 | $0 | -100.0% | $0 | - | $-16,518,999 | - |
| 2018 | $1.2M | - | $1.2M | 100.0% | $-7,259,000 | -583.5% |
See LYRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LYRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LYRA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLYRA — Frequently Asked Questions
Quick answers to the most common questions about buying LYRA stock.
Is LYRA's revenue growth accelerating or slowing?
LYRA revenue declined -87.2% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $600000.00. This reverses the prior growth trend.
What is LYRA's long-term revenue growth rate?
Lyra Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -87.2% is below this long-term average.
How is LYRA's revenue distributed by segment?
LYRA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.